All In Biotech

Drug Trial Radar · NCT02766621

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

Phase 1, Randomized, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of Pf-06823859 In Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

May 27, 2016

Primary completion

Aug 30, 2017

Study completion Sep 26, 2017

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF 06823859 in healthy subjects.

Conditions

  • Healthy

Interventions

  • PF-06823859Biological

    Comparison of different dosages of PF-06823859 to placebo

  • Placebo injection SC/IVDrug

    Comparison of Placebo to different doses of PF-06823859

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEsTime frame: Dosing through approximately Day 189

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer New Haven Clinical Research Unit

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.